Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

February 8, 2021

Study Completion Date

June 30, 2021

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tc 99m tilmanocept

Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Trial Locations (10)

15213

University of Pittsburgh Medical Center, Pittsburgh

16635

Altoona Center for Clinical Research, Duncansville

33157

Innovation Medical Research Center, Palmetto Bay

44106

University Hospitals, Cleveland

45429

Kettering Medical Center, Kettering

68516

Physician Research Collaboration, Lincoln

74136

Central States Research, Tulsa

85258

Imaging Endpoints, Scottsdale

90036

Axis Clinical Trials, Los Angeles

94110

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY